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Abstract  
Aims 
Maternal obesity is associated with heightened risk of gestational diabetes 
(GDM). This study has addressed the prediction of GDM in obese women by 
routine clinical measures and measurement of biomarkers related to insulin 
resistance in the early second trimester. 
 
Methods 
117 obese pregnant women participating in a pilot trial of a complex 
intervention of dietary advice and physical activity were studied. Blood 
samples were obtained at recruitment (15+0-17+6) weeks and demographic, 
clinical history and anthropometric measures recorded. Biomarkers analysed 
were plasma lipids (HDL-c, LDL-c, triglycerides), high-sensitivity C-reactive 
protein [hs-CRP], alanine transaminase [ALT], aspartate transaminase [AST], 
ferritin, fructosamine, insulin, adiponectin, tissue plasminogen activator [t-PA], 
interleukin-6 [IL-6], visfatin and leptin). Univariate followed by logistic 
regression analyses was performed to determine independent predictors and 
area under the receiver-operating curve (AUC-ROC) calculated for the model.  
 
Results 
Of the 106 women included in the analysis, 29 (27.4%) developed GDM. 
Women with GDM were older, more often of parity ≥2, had higher systolic and 
diastolic blood pressure, and were more likely to be black (all p<0.05). 
Amongst the blood biomarkers measured, plasma adiponectin alone 
remained independently associated with GDM in adjusted models (p=0.002). 
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The AUC-ROC for clinical factors alone (0.760) increased significantly (AUC 
0.834, Ch2(1) =4.00, p=0.046) with the addition of adiponectin.   
 
Conclusions 
A combination of routinely measured clinical factors and adiponectin 
measured in the early second trimester in obese women may provide a useful 
approach to the prediction of GDM. Validation in a large prospective study is 
required to determine usefulness in clinical practice. 
 
Clinical Trial Reference: ISRCTN89971375 
 
Keywords: gestational diabetes, prediction, adipokines, adiponectin, obesity, 
pregnancy 
 
Abbreviations: alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), gestational diabetes (GDM), high sensitivity C-reactive protein (hs-
CRP), interleukin 6 (IL-6), International Associatio  of Diabetes Pregnancy 
Study Groups (IADPSG), tissue plasminogen activator (t-PA), Body Mass 
Index (BMI). 
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Introduction 
The prevalence of obesity in adults and children continues to rise. Obesity 
remains the sixth most important determinant of adverse health and reduced 
adult life expectancy globally [1]. In the UK, the incidence of obesity in women 
of reproductive age has almost doubled in the past twenty years [2]; the most 
recent WHO Global Infobase of obesity (BMI ≥30kg/m2) in UK females aged 
more than 15 years (2010) reports an age adjusted prevalence of obesity  of 
26.3% across all ethnic groups [3].  
 
Maternal obesity carries significant risk of adverse pregnancy outcome, 
particularly gestational diabetes (GDM). Short and long term metabolic 
complications follow a continuous linear relationship with BMI [4, 5] with the 
risk of developing gestational diabetes (GDM) rising from two to eightfold 
across increasing BMI category [6].  Not all obese women develop GDM, 
however this heterogeneity poses a burden on limited resources with all 
women with a BMI >30Kg/m2 currently managed as if at risk, often resulting in 
sub-optimal management. Accurate and early identification of pregnant obese 
women who will subsequently develop GDM women would enable early risk 
stratification, more appropriate use of health care resources and targeting of 
intervention strategies.  
 
Currently, the UK National Institute for Health and Clinical Excellence (NICE) 
recommend selected rather than universal GDM screening, according to risk 
factors which include obesity. Women with who have previously delivered a 
macrosomic infant, have had previous GDM, or who have a first degree 
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relative with diabetes and high risk ethnicity are also screened. This approach 
yields 60% detection of GDM with a 40% false positive rate in all women [7]. 
Whilst there is at present no accepted early pregnancy intervention to improve 
clinical outcome in obese pregnant women [8-10], increased recognition of the 
problem [11] has led to an international research effort to develop effective 
interventions. Several large–scale, randomised control trials (RCTs), including 
the UK Better Eating and Activity Trial (UPBEAT; ISRCTN89971375), are 
investigating targeted dietary and lifestyle interventions or pharmacological 
approaches to improve pregnancy outcome in overweight and obese women 
[12-14].  
 
Research into the prediction of adverse outcomes in other pregnancy related 
conditions such as pre-eclampsia has shown that a combination of clinical 
history and early pregnancy clinical measures, together with addition of 
biomarkers measured in biological samples may provide an effective strategy 
in early pregnancy risk assessment [15]. Several studies have adopted this 
approach in prediction of GDM [16, 17], but to our knowledge, not previously 
in a population of obese women. 
 
In addition to routine demographical data and clinical measurements recorded 
in early pregnancy in obese women, we have measured biomarkers 
implicated in the pathogenesis and prediction of type 2 diabetes which reflect 
inflammatory pathways, markers of adipose tissue function and hepatic fat 
accumulation and measures of vascular dysfunction [18-21]. These were 
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evaluated at recruitment in women participating in a pilot trial for the UPBEAT 
study.  
 
Methods 
UPBEAT is a multi-center RCT of a complex dietary and physical activity 
intervention aimed at improving glucose homeostasis in obese pregnant 
women (current controlled trials register: ISRCTN89971375). A pilot trial was 
undertaken in 183 women in four UK hospitals to evaluate changes in dietary 
and physical activity behaviours, trial all aspects of the protocol and to 
undertake process evaluation.  Details of the intervention and protocol are 
available on the trial web site (http://www.medscinet.net/upbeat/about.aspx). 
 
Ethical Approval: NHS Research Ethics Committee approval was obtained in 
all contributing centres (UK IRAS integrated research application system; 
reference 09/H0802/5).  
 
At recruitment (15+0-17+6 weeks gestation) and following informed consent, 
information was obtained on demography, maternal history, maternal family 
and current pregnancy health. One week later, women were randomised to 
the intervention arm or control arm, which consists of standard antenatal care.  
Blood pressure was recorded using the Microlife® BP3BT0-A automated blood 
pressure monitor which is validated for use in pregnancy. Maternal skinfold 
thickness (triceps, biceps, subscapular and supra-iliac) were measured in 
triplicate with Harpenden skinfold calipers (validated for values ≤80mm) 
(Holtain Ltd, Wales, UK) in addition to the following circumferences: waist, mid 
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arm, thigh and hip. Total sum of skinfolds was calculated at four sites (triceps, 
biceps, suprailiac and subscapular). Blood samples were obtained from 117 
women in the three centres that had facilities for sample handling and 
storage. Serum and plasma was stored at -80°C for future analysis. 
 
At 28 weeks’ gestation an oral glucose tolerance test was performed on all 
women. Diagnosis of GDM following a 75g 2-h OGTT at 27+0-28+6 weeks’ was 
defined according to the International Association of Diabetes Pregnancy 
Study Groups (IADPSG) criteria (fasting blood glucose ≥5.1mmol/l or 1-hr 
glucose ≥10.0mmol/l or 2-hr glucose ≥8.5mmol/l)[22]. If a diagnosis of GDM 
was made, women were referred for routine GDM care according to local 
criteria. 
 
Biochemical analyses: plasma total cholesterol, HDL-cholesterol triglycerides, 
ALT, AST, hs-CRP, fructosamine (c311, Roche Diagnostics, Burgess Hill, UK) 
and ferritin (elecsys 2010, Roche Diagnostics, Burgess Hill, UK) were 
measured on clinically validated automated platforms  using the 
manufacturers’ quality controls and calibration materials. Coefficients of 
variation (CVs) were <6%. Plasma insulin was measured with an enzyme 
linked immunosorbent assay (ELISA) (Mercodia, Uppsala, Sweden) that does 
not cross-react with proinsulin and the interassay CV was <7%.  Baseline 
plasma adiponectin, IL-6, leptin (R&D Systems, Abingdon, U.K.)  t-PA (Stago, 
Theale, UK) and visfatin (Phoenix peptide, Karlsruhe, Germany) were 
measured by enzyme-linked immunosorbent assay. These methods had inter-
assay CV’s <10%.  
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All analyses were performed on previously unthawed EDTA and serum 
samples. Samples were processed by technicians blinded to the identity of 
the samples. 
 
Statistical methods 
The analysis was essentially exploratory with the aim of identifying potentially 
useful combinations of clinical and biochemical predictors of maternal GDM. 
Standard distributional checks (BoxCox regression and Normal distribution 
plots) were carried out, and separate decisions made on the appropriate 
transformation. Based on these findings, log transformation was made for all 
biochemical variables. Differences between patient groups are reported as 
geometric means and ratios of geometric means, with 95% confidence 
intervals.   
 
The association of clinical indicators with GDM was established using linear or 
logistic regression as appropriate, with robust standard errors.  Biochemical 
indicators were assessed as predictors of GDM, adjusting for significant 
clinical indicators.   
 
The overall performance of the markers as predictors of GDM was assessed 
by comparison of ROC areas.  Where necessary, composite predictors were 
derived using multiple logistic regression.  
 
All data analysis was carried out in the statistical package Stata, version 11.2 
(StataCorp, College Station, Texas). 
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Results 
11 women were omitted from analysis because of inadequate OGTT data. Of 
the remaining 106, 29 were diagnosed with GDM (27.4%). Demographic and 
clinical characteristics of women who developed GDM compared to those who 
did not are summarised in Table 1.  In general, women with GDM were older, 
more often of higher parity (≥2), had increased systolic and diastolic blood 
pressure and were more likely to be black. BMI was not significantly different 
between the two groups, although skinfold thicknesses were greater in 
women who developed GDM; women who developed GDM had greater 
triceps (37.40mm v 31.36mm p=0.004) and total sum of skinfolds thickness 
(93.88mm v 86.06mm p=0.031). There was no evidence of interaction in 
terms of prediction of GDM by treatment group (p=0.85). 
 
Table 2 summarises the first trimester biomarkers for women who 
subsequently developed develop GDM and those who did not.  Women with 
GDM had 34% lower plasma concentrations of adiponectin [95% CI -47% to -
19%], adjusting for clinical predictors: age, parity ≥2, DBP and SBP. There 
was a trend towards significance for fructosamine in the GDM group (p=0.05), 
which attenuated to the null following adjustment (p=0.82). No other 
biochemical markers were associated with GDM (Table 2).  
 
In a combined logistic regression model including the biomarkers and clinical 
risk factors, the only consistent predictive variables were adiponectin (OR for 
a halving in adiponectin concentration 4.04 [95% CI 1.69 to 9.64], p= 0.002) 
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and maternal age (OR per additional year 1.179, [95% CI 1.04 to 1.337], 
p=0.01) (Table 3).  
 
An AUC-ROC of 0.760 [95% CI 0.645 to 0.875] for prediction of GDM was 
achieved with clinical predictors (age, parity, ethnicity and blood pressure) 
alone. The AUC-ROC increased significantly to 0.834 [95% CI 0.742 to 0.927] 
(Ch2(1)=4.00, p=0.046) with addition of adiponectin (Figure 1).  
 
Further sensitivity analysis was conducted with addition of maternal 
anthropometry increasing the AUC-ROC for clinical predictors alone to 0.796 
[95% CI 0.692 to 0.898] (supplement Table 1) however in the fully adjusted 
model, only a low concentration of adiponectin remained independently 
predictive of GDM.  
 
Discussion 
This study highlights novel biochemical and clinical factors for the prediction 
of GDM in obese pregnant women and suggests that an algorithm based on 
simple clinical variables plus adiponectin may provide a clinically useful 
method for prediction of GDM in this population.  
 
Four previous studies have identified a number of patient characteristics and 
biomarkers associated with the prediction of GDM [16, 23-25]. These have 
been undertaken in populations of mixed risk, including non-caucasian 
ethnicity [16, 23, 25], a family history of diabetes [16, 23-25], previous history 
of GDM [16, 23, 25], increased pre-pregnancy BMI [16, 24, 25], increased 
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maternal age [16, 23, 25]  and  of differing parity [24]. Savvidou et al 
measured nine biomarkers in the first trimester and found that high tPA and 
low HDL increased the AUC-ROC from 0.824 with clinical risk factors alone to 
0.861 in a group of all comers regardless of baseline BMI [24]. The addition of 
adiponectin to prediction models for GDM has consistently increased the 
AUC-ROC to values above those achieved with clinical measures alone. 
Further inclusion of adipokines and biomarkers has frequently demonstrated a 
modest, non-significant increase in the AUC-ROC. For example, in a case 
controlled study of 400 women, those with GDM were reported to have 
increased maternal serum visfatin and decreased serum adiponectin 
concentrations at 11-13 weeks. The addition of adiponectin to the prediction 
model using clinical measures alone resulted in a significant change in the 
AUC-ROC whereas there was a non-significant increase following addition of 
visfatin (AUC-ROC 0.828 [maternal characteristics alone], 0.854 [adiponectin] 
and 0.855 [adiponectin and visfatin]) [16]. Nanda et al measured three 
biomarkers and found that in the GDM group, compared to controls, 
adiponectin and sex hormone-binding globulin (SBGH) were lower. When 
screening for GDM by maternal characteristics alone, the detection rate was 
61.6% (false-positive rate of 20%) increasing to 74.1% with the addition of 
adiponectin and SHBG [25]. Alternative approaches to GDM risk assessment 
have included measurement of biomarkers in the preconception period, a 
recent report finding that maternal characteristics, fasting plasma glucose, 
glycosuria and preconception dyslipidaemia yielded an AUC-ROC of 0.90 for 
the prediction of GDM [23].  However, the varied diagnostic criteria for GDM 
used in previous studies has limited comparisons between previous attempts 
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to predict GDM. Importantly, none has specifically addressed risk assessment 
in obese pregnant women, which has important implications for clinical 
practice given the recognition of obesity as the major risk factor for GDM, and 
the likelihood that the biomarker profile may be dissimilar from other risk 
groups in women with a high BMI.   
 
Our results suggest that clinically useful prediction of GDM in obese pregnant 
women is achievable using a combination of clinical characteristics (older age, 
increased blood pressure [SBP and DBP], parity ≥2 and black ethnicity) 
combined with the plasma concentration of adiponectin. To reflect current 
clinical practice, routine clinical measurements recorded at antenatal visits 
were included. The inclusion of detailed maternal anthropometry (including 
skin-fold thicknesses), which is undertaken in all women participating in the 
UPBEAT trial suggested a limited potential role for taking such measurements 
routinely as an aid to GDM prediction (supplement  Figure 1).  
 
Adiponectin, an adipocyte derived adipokine, is ow recognised as being 
strongly associated with improved glucose metabolism and increasing insulin 
sensitivity, although the causality of this relationship remains debated. 
Irrespective of causal direction, adiponectin appears to provide a good ‘read-
out’ of whole body insulin sensitivity. In a recent meta-analysis of non-
pregnant individuals adiponectin was shown to be strongly predictive of type 2 
diabetes, and inversely related to measures of insulin resistance and BMI 
[18]. 
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The role of adiponectin in obese pregnant women may extend beyond 
usefulness as a biomarker. In the Hyperglycemia and Adverse Pregnancy 
Outcome (HAPO), serum concentrations of adiponectin declined as glucose 
and maternal BMI increased and adiponectin was inversely associated with 
birth weight, neonatal skin fold thickness and total body fat (estimated using 
anthropometry), giving rise to the hypothesis that this cytokine may play a role 
in fetal growth regulation by modulation of placental nutrient transport in 
addition to maternal glucose homeostasis [26]. Data in support of a placental 
origin of adiponectin  remains equivocal, with evidence favouring maternal 
origin of adiponectin measured in the blood of pregnant women [27]. Maternal 
adiponectin has, therefore, the potential to be a ‘functional’ target for 
interventions in obese pregnant women whereby achievement of increased 
plasma concentrations could parallel a reduced risk of macrosomia. This may 
be a realistic target as adiponectin has been shown to be modifiable by 
dietary intervention in non-pregnant populations [28, 29]. Lifestyle 
interventions in pregnant women of differing pre-pregnancy BMI categories 
have been equivocal in regard to effects on glucose metabolism and insulin 
resistance although none has measured adiponectin [30-32]. Following 
completion of the UPBEAT (1546 women), the influence of the intervention on 
plasma adiponectin concentration will therefore be explored.  
 
To the best of our knowledge there have been no previous studies of 
adiponectin and GDM in an exclusively obese population but the findings are 
consistent with other reports in women of all BMI categories with established 
disease or prior to the development of GDM [25, 33, 34]. A recent case 
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controlled study from Brazil of 79 and 129 women of mixed ethnicity with and 
without GDM respectively, reported that GDM was associated with 
significantly lower serum concentrations of adiponectin in the third trimester 
(28-36 weeks) compared to controls (p=0.0015). GDM and BMI both had an 
independent association with adiponectin with no significant interaction 
between the two factors (GDM: p = 0.04, BMI: p= 0.01 and interaction: p = 
0.76 following a two-way ANOVA test) [35]. In contrast, although adiponectin 
was significantly lower in women who developed GDM in our previous study 
in women of mixed risk [24], it did not contribute to the final model which 
combined two factors (HDL-c and t-PA antigen), both recognised to be related 
to adiponectin via linked hepatic / circulating triglyceride-mediated pathways 
[36] .  
 
Low serum adiponectin concentrations appear to be associated with ethnic 
groups known to have a higher risk of developing incident type 2 diabetes 
later in life [37]. In the present study, women of black ethnic origin had 
significantly lower plasma levels of adiponectin than non-black women, and a 
previous report has shown lower adiponectin concentrations in pregnant 
women of South Asian origin [33].  
 
We also observed that adiponectin was significantly related to current 
smoking status, a finding previously reported in a non-pregnant population in 
which the plasma adiponectin concentration increased in a stepwise fashion 
with never, past and current smokers [38, 39].  
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There were limitations to our study.  The sample size was small and the data 
obtained should be considered as a training set for later validation in the 
UPBEAT trial. Furthermore, fasting blood samples were not obtained at 
randomisation (15+0-17+6), precluding the measurement of the fasting glucose 
or insulin concentration. However, as fasting is not mandatory for antenatal 
clinic visits, this study was designed pragmatically, to be relevant to current 
clinical practice. 
  
In summary, we have demonstrated that the risk of developing GDM in obese 
pregnant women may be predicted in the early second trimester of pregnancy 
by using an algorithm, which incorporates routine clinical variables as well as 
the biochemical marker adiponectin. Our findings therefore extend prior 
studies and collectively suggest that by additionally measuring adiponectin in 
high-risk women before routine clinical diagnosis of GDM, a potential 
therapeutic window for intervention could be created. Since GDM is 
associated with increased risk of incident type 2 diabetes and 10 year 
cardiovascular risk in mothers [40], as well as maternal and neonatal 
pregnancy complications, successful intervention has the potential to improve 
both short and long term outcomes. We conclude that further large scale 
studies of GDM prediction in obese pregnant women are warranted.  
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Table 1 
Simple unadjusted comparisons of clinical predictors by OGTT test result 
Maternal 
Characteristic 
GDM (IADPSG) 
N=29 
No GDM 
N=77 
Comparison (95% CI) P value 
Age (years)  
Age categories  
    18-25      
    26-30  
    31-40  
    35 plus                                   
33.48 (±4.40) 
 
2 (6.9%) 
4 (13.8%) 
10 (34.5%) 
13 (44.8%) 
30.19 (±5.31) 
 
17 (22.1%) 
20 (26.0%) 
26 (33.8%) 
14 (18.2%) 
3.29 ( 1.28 to  5.30) 
 
- 
1.70 (0.28 to 10.45) 
3.27 (0.64 to 16.80) 
7.89 (1.52 to 41.02) 
0.002 
0.030 
- 
- 
- 
- 
Height (m)  
Weight (kg) 
BMI (kg/m
2
)                        
1.65 (±0.08) 
95.79 (±12.38) 
35.27 (±3.60) 
1.65 (±0.07) 
97.98 (±15.56) 
36.11 (±4.95) 
0.00 (-0.03 to  0.03) 
-2.19 (-7.93 to  3.54) 
-0.84 (-2.57 to  0.89) 
0.944 
0.450 
0.337 
Circumferences (cm) 
Waist 
Mid arm  
Hip  
Thigh             
 
107.83 (±7.42) 
37.83 (±4.05) 
120.48 (±9.23) 
66.41 (±8.97) 
 
107.56 (±10.75) 
37.21 (±3.98) 
122.87 (±11.80) 
69.36 (±7.69) 
 
0.27 (-3.37 to  3.91) 
0.62 (-1.11 to  2.35) 
-2.39 (-6.69 to  1.92) 
-2.95 (-6.66 to  0.76) 
 
0.884 
0.479 
0.274 
0.118 
Skinfolds (mm) 
Triceps 
Biceps 
Subscapular 
Suprailiac 
Total 
 
37.40 (±10.15) 
28.00 (±9.54) 
35.97 (±8.19) 
29.91 (±8.28) 
93.88 (±16.47) 
 
31.36 (±7.36) 
24.42 (±7.50) 
32.22 (±9.15) 
29.73 (±8.26) 
86.06 (±16.65) 
 
6.04 ( 1.98 to 10.10) 
3.58 (-0.30 to  7.46) 
3.74 ( 0.10 to  7.39) 
0.18 (-3.38 to  3.74) 
7.82 ( 0.72 to 14.92) 
 
0.004 
0.070 
0.044 
0.920 
0.031 
SBP (mmHg)  
DBP (mmHg)                  
123.31 (±7.89) 
76.44 (±7.52) 
119.04 (8.68) 
72.54 (6.65) 
4.26 ( 0.77 to  7.75) 
3.90 ( 0.77 to  7.03) 
0.017 
0.015 
Ethnicity 
     Black 
     Asian 
     Other 
 
16/29 (±55.2%) 
0/29 (±0.0%) 
2/29 (±6.9%) 
 
21/77 (±27.3%) 
1/77 (±1.3%) 
2/77 (±2.6%) 
 
3.28 (1.35 to 7.97) 
0.00 (0.00 to ∞ ) 
2.78 (0.37 to 20.70) 
 
0.009 
0.991 
0.319 
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Parity 
     0 
     1 
     2 or more           
 
9 (31%) 
10 (34.5%) 
10 (34.5%) 
 
37 (48.1%) 
31 (40.3%) 
9 (11.7%) 
 
- 
1.33 (0.48 to 3.67) 
4.57 (1.43 to 14.55) 
 
- 
- 
- 
Previous GDM   1/29 (±3.4%) 1/77 (±1.3%) 2.71 (0.16 to 44.88) 0.485 
Smoking 
     Never 
     Current 
Number of cigarettes 
(<8 weeks) 
     0 
     1-5 per day         
     6-10 per day 
     11-20 per day       
 
8/29 (27.6%) 
2/29 (6.9%) 
 
 
27 (93.1%) 
2 (6.9%) 
0 (0.0%) 
0 (0.0%) 
 
33/77 (42.9%) 
5/77 (6.5%) 
 
 
66 (85.7%) 
2 (2.6%) 
5 (6.5%) 
4 (5.2%) 
 
0.51 (0.20 to 1.29) 
1.07 (0.20 to 5.83) 
 
 
- 
2.44 (0.33 to 18.25) 
- 
- 
 
0.154 
0.941 
 
- 
- 
- 
- 
- 
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Table 2 
Comparisons of biomarkers by OGTT test result (geometric means & ratios). 
(adjusted for routinely used clinical predictors: age, parity (>=2), Black ethnicity, SBP and DBP) 
 
Biomarker* GDM (IADPSG)  No GDM      Comparison (95% CI)       P value 
Fructosamine (umol/l) n=28 200.87 (1.10)     n=77 192.90 (1.09)     1.00 (0.97 to 1.04) 0.816 
ALT (U/L) n=28 21.41 (1.79)      n=77 19.00 (1.57)      1.12 (0.84 to 1.50) 0.423 
AST (U/L) n=28 30.63 (1.53)      n=77 25.07 (1.41)      1.17 (0.96 to 1.43) 0.109 
Ferritin (ng/ml) n=28 42.06 (2.27)      n=77 39.48 (2.29)      0.95 (0.64 to 1.41) 0.785 
Adiponectin (µg/ml) n=28 4.97 (1.72)       n=77 7.34 (1.76) 0.66 (0.53 to 0.81) 0.000 
tPA (ng/ml) n=28 10.35 (1.49)      n=77 9.00 (1.47)        1.05 (0.86 to 1.28) 0.644 
iL-6 (pg/ml) n=27 1.01 (2.08)       n=75 0.95 (2.54)        0.91 (0.66 to 1.24) 0.547 
Leptin (pg/ml) n=28 53.82 (1.49)      n=74 59.36 (1.52)      0.92 (0.76 to 1.13) 0.438 
Visfatin (ng/ml) n=28 4.94 (1.40)       n=74 5.28 (1.42)        0.93 (0.77 to 1.12) 0.416 
Insulin (mU/l) n=29 26.00 (2.99)      n=77 20.20 (2.78)      1.33 (0.80 to 2.21) 0.270 
Cholesterol (mmol/l) n=29 5.31 (1.18)       n=77 5.42 (1.21)        1.01 (0.93 to 1.10) 0.801 
Triglycerides (mmol/l) n=29 1.67 (1.42)       n=77 1.53 (1.38)        1.13 (0.96 to 1.32) 0.134 
HDL (mmol/l) n=29 1.64 (1.32)       n=77 1.71 (1.26)        0.94 (0.82 to 1.08) 0.391 
CRP (mg/l) n=29 9.18 (1.93)       n=77 7.77 (2.30)        1.28 (0.89 to 1.83) 0.179 
VLDL (mmol/l) n=29 0.76 (1.42) n=77 0.71 (1.38)        1.13 (0.97 to 1.32) 0.118 
LDL (mmol/l) n=29 2.74 (1.39)       n=77 2.93 (1.34)        0.99 (0.86 to 1.14) 0.862 
Cholesterol:HDL n=29 3.23 (1.31)       n=77 3.17 (1.27)        1.07 (0.95 to 1.21) 0.265 
LDL:HDL n=29 1.67 (1.56)       n=77 1.71 (1.45)        1.05 (0.87 to 1.27) 0.631 
*indicates geometric means and ratios of geometric means 
Only adiponectin predictive after allowing for major clinical variables. 
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Table 3 
Combined logistic regression using biomarkers and routine clinical risk factors that were significant in 
tables 1 and 2 (age, parity [>=2], Black ethnicity, SBP, DBP and adiponectin)     
 
 Odds Ratio Std. Error z P>|z| 95% Conf. Interval 
Log adiponectin 0.1333 0.853 -3.15 0.002 0.038 to 0.467 
Age 1.179 0.076 2.57 0.010 1.040 to 1.337 
Parity ≥2 2.091 1.524 1.01 0.312 0.501 to 8.725 
Black ethnicity 1.349 0.802 0.50 0.615 0.420 to 4.328 
SBP 1.038 0.047 0.83 0.409 0.950 to 1.134 
DBP 1.075 0.054 1.45 0.148 0.975 to 1.186 
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Figure 1 
 
 
 
Figure 1: ROC curve and summaries using the basic model (including age, parity, ethnicity, 
blood pressure), with the addition of adiponectin. AUC, area under ROC curve.   
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Supplement 1 (Online Appendix File) 
 
Table 1 
Combined logistic regression using biomarkers and routine clinical risk factors that were 
significant in supplement tables 1 and 2  
(age, parity [>=2], Black ethnicity, SBP, DBP, triceps skinfold, total sum of skinfold and 
adiponectin)     
 
 Odds Ratio Std. Error z P>|z| 95% Conf. Interval 
Log adiponectin 0.179 0.120     -2.57 0.010 0.048 to 0.666 
Age 1.148   0.075     2.11    0.035 1.010 to 1.305 
Parity ≥2 3.382    2.597      1.59    0.113 0.751 to 15.236 
Black ethnicity 0.795    0.545     -0.33 0.738 0.207 to 3.048 
SBP 1.004    0.050     0.08 0.932 0.912 to 1.106 
DBP 1.092    0.058      1.66 0.098 0.984 to 1.212 
Triceps skinfold 1.072   0.047      1.58 0.115 0.983 to 1.169 
Total skinfold 1.005 0.023     0.22 0.823 0.961 to 1.051 
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